China Securities Intelligent Financial News Bloomage Biotech (688363) disclosed its 2024 performance report on the evening of February 27, and the company achieved operating income of 5.371 billion yuan, a year-on-year decrease of 11.6%; the net profit attributable to the parent company was 164 million yuan, a year-on-year decrease of 72.27%; deducted non-net profit of 101 million yuan, a year-on-year decrease of 79.36%; The basic earnings per share was 0.34 yuan, and the weighted average return on equity was 2.34%. Based on the closing price on February 27, Bloomage Biotech's current price-to-earnings ratio (TTM) is about 149.21 times, the price-to-book ratio (LF) is about 3.49 times, and the price-to-sales ratio (TTM) is about 4.28 times.

Based on the data of this disclosed performance report, the company's price-to-earnings ratio (TTM) chart in recent years is as follows:

According to the data, the company is a world-renowned biotechnology company driven by synthetic biotechnology innovation, and a platform company for the whole industrial chain of biomaterials, with two major technology platforms of microbial fermentation and cross-linking, as well as six major R&D platforms including pilot transformation platform, formula process R&D platform, synthetic biology R&D platform and application mechanism R&D platform, the company has established a whole industry chain business system of bioactive materials from raw materials to medical terminal products, functional skin care products and functional foods, serving the global pharmaceutical, cosmetics, Manufacturing enterprises, medical institutions and end users in food and other fields.

During the reporting period, the company's raw materials business maintained steady growth, mainly benefiting from the company's localization operations promoted in the internationalization strategy, and the sales volume in Europe, Japan, the Americas and other places achieved continuous growth, further consolidating its leading position in the global bioactive substances market. The company's medical terminal business has maintained rapid growth, and its medical aesthetic brand Runzhi has launched two new medical aesthetic injections, which are expected to bring further growth space to the company's medical aesthetic business; At the same time, through endogenous and epitaxial methods, we will accelerate the promotion of various medical aesthetic pipelines and enrich the company's product line. The company's functional skin care products business, which accounts for a high proportion of revenue, is affected by various factors such as intensified market competition, industrial cycle fluctuations and strategic adjustments, and the adjustment is still ongoing, and the business foundation is continuously consolidated from process to organization and operation, talent training, product system construction, etc., and the functional skin care products business is expected to bottom out in 2025.

During the reporting period, the company adhered to and continued to implement management reform and promote the implementation of management reform projects. Due to the upgrading of the organizational structure, the reform of the compensation system, the fees of the consulting company and the equity incentive expenses of more than 70 million yuan, the management reform has brought about a certain short-term cost increase, but it has laid a solid foundation for the long-term development of the company.

The company increased long-term, strategic and front-loading investment, including promoting the transformation of the supply chain, improving production efficiency and intelligence, and implementing the production capacity layout including Haikou, Tianjin, Dongying, Xiangtan, etc., and increasing related expenses by more than 100 million yuan, further consolidating the advantages of the whole industry chain.

According to the data, the company's weighted average return on equity in 2024 will be 2.34%, down 5.97 percentage points from the same period last year.

Proofreading: Yang Ning

Indicator Annotation:

P/E ratio = total market capitalization / net profit. When the company loses money, the P/E ratio is negative, and it is not practical to use the P/E ratio for valuation, and the P/B ratio or P/B ratio is often used as a reference.

Price-to-book ratio = total market capitalization / net assets. The price-to-book ratio valuation method is mostly used for companies with large fluctuations in earnings and relatively stable net assets.

Price-to-sales ratio = total market capitalization / operating income. The price-to-sales ratio method is often used for growing companies that are losing money or making small profits.

The price-to-earnings ratio and price-to-sales ratio in this article are calculated using the TTM method, that is, the data for the 12 months up to the latest financial report (including forecast). The price-to-book ratio is calculated using the LF method, that is, based on the latest financial report data. The quantile calculation range of the three is from the company's listing to the latest announcement date.

When the P/E ratio and price-to-book ratio are negative, the current quantile is not displayed, which will cause the line chart to be interrupted.